CCCC Earnings Date: Nov 5, 2026 (Estimated) — C4 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CCCC's next earnings date?
C4 Therapeutics, Inc. (CCCC) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.19 on revenue of $8.5M.
How did CCCC do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), C4 Therapeutics, Inc. posted EPS of -$0.18 versus the -$0.23 estimate, a beat of 21.7%. Revenue was $6.6M against a $4.0M estimate. The stock's 1-day post-earnings move was +6.9%.
How much does CCCC stock move after earnings?
CCCC beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.23 | -0.18 | +21.74% | $6.6M | ✅ Beat | +6.91% | +17.82% | -4.97% |
| 2026-05-12 | Q1 2026 | -0.25 | -0.20 | +20.00% | $6.2M | ✅ Beat | +0.00% | +1.58% | +22.08% |
| 2026-02-26 | Q4 2025 | -0.41 | -0.18 | +56.10% | $11.0M | ✅ Beat | +0.36% | +11.55% | -5.42% |
| 2025-11-06 | Q3 2025 | -0.42 | -0.44 | -4.76% | $11.2M | ❌ Miss | +0.42% | +4.64% | +12.66% |
| 2025-08-07 | Q2 2025 | -0.38 | -0.37 | +2.63% | $6.5M | ✅ Beat | +31.63% | +18.88% | +38.78% |
| 2025-05-07 | Q1 2025 | -0.42 | -0.37 | +11.90% | $7.2M | ✅ Beat | +6.38% | +6.38% | +4.26% |
| 2025-02-27 | Q4 2024 | -0.37 | -0.49 | -32.43% | $5.2M | ❌ Miss | -1.89% | -8.30% | -30.57% |
| 2024-10-31 | Q3 2024 | -0.38 | -0.35 | +7.89% | $15.4M | ✅ Beat | -3.62% | +7.96% | -17.72% |
Showing last 8 quarters.